Phathom Pharmaceuticals, Inc. (PHAT) · Oct 26, 2026 · Other events

Phathom FDA docket widens VOQUEZNA exclusivity fight

FDA comment docket — Comments due November 23, 2026; exclusivity remains in effect

Phathom’s FDA docket adds another legal hurdle around VOQUEZNA’s 2032 exclusivity, but the protection remains in effect for now.

Phathom is a commercial-stage GI company building its business around the growing U.S. launch of VOQUEZNA while advancing additional vonoprazan uses, including non-erosive GERD and eosinophilic esophagitis. VOQUEZNA generated $74.3 million of second-quarter 2026 revenue, and the company had reported roughly 1.7 million prescriptions filled by July 2026. The filing does not remove current protection, but it turns a previously contained exclusivity dispute into a broader administrative and litigation process. The FDA has opened a public docket on the legal and regulatory questions raised by BDR, with comments due November 23, 2026. 〔0〕 A second purported ANDA filer, Saba Ilac, also says it intends to seek consolidation with BDR’s case. 〔1〕 The near-term business position is unchanged, but the downside scenario is more credible than it was before this notice. Phathom still says VOQUEZNA’s 10-year NCE exclusivity runs through May 3, 2032, and the filing states that the exclusivity “remains in effect.” 〔2〕 However, an adverse FDA or court outcome could allow generic applications to be received or approved earlier, putting the company’s core commercial franchise at risk. This is not a loss of exclusivity today; it is an expansion of the process that could determine how long the protection lasts. Bottom line: The filing is mixed rather than an immediate setback: VOQUEZNA keeps its claimed protection for now, but the exclusivity challenge now involves both a formal FDA comment process and a second potential challenger.

What to watch next

FDA docket comments due November 23, 2026

Original filing on SEC EDGAR

More Phathom Pharmaceuticals, Inc. news

Phathom FDA docket widens VOQUEZNA exclusivity fight | PHAT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.